In the food allergy world, there is continuing research to identify the cause of allergies. One area of research has been to look at the difference in allergy rates in infants born vaginally and those cesarean births. New research conducted by Murdoch Children's Research Institute (MCRI), examines this issue with interesting results.
Cesarean births are not linked to an increased risk of food allergy during the first year of life, according to a new study.
The research, led by the Murdoch Children's Research Institute (MCRI) and published in the Journal of Allergy and Clinical Immunology: In Practice, found cesarean delivery, either with or without labor, or elective or emergency, compared to vaginal birth does not impact on the likelihood of food allergy at 12 months of age.
To have a life-threatening food allergy means you must be vigilant. Reading labels, asking restaurant staff what the ingredients in a meal are as well as its preparation. And it’s on going; you don’t get a day off from your food allergies. But now a new product provides additional help in your quest to stay safe; the Allergy AmuletTM described as “the world’s smallest and fastest consumer food allergen sensor that tests for common allergenic ingredients in seconds”.
Amulet, the company making the world’s smallest, fastest, and sleekest molecular detection technology capable of sensing everything from pathogens in the air to pesticides in produce, today announces its official launch. Amulet is the company behind Allergy Amulet™, a consumer brand with a signature wearable that alerts people to allergens in their food, and Amulet Scientific™, a commercial brand that equips industry with a detection platform for identifying a range of molecular targets, including food toxins and environmental contaminants.
Having the opportunity to have “an orally delivered epinephrine” could be a game changer. Recently Aquestive Therapeutics, Inc. (NASDAQ:AQST), announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AQST-109, “the first and only orally delivered epinephrine-based product candidate for the emergency treatment of allergic reactions, including anaphylaxis”. The FDA Fast Track process is “designed to facilitate the development and expedite the review of potential therapies that seek to treat serious conditions and fill unmet medical needs.”
Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AQST-109, the first and only orally delivered epinephrine-based product candidate for the emergency treatment of allergic reactions, including anaphylaxis.
“We are focused on continuing to develop and, if approved, bringing this transformative product to patients and caregivers given its potential to significantly improve how they manage anaphylaxis,” said Keith Kendall, Chief Executive Officer of Aquestive. “Fast Track designation is an indication that the FDA recognizes that AQST-109, if approved, fulfills a significant unmet need. An epinephrine oral film like AQST-109 would provide patients with a rescue medication where they need it, when they need it, and in a form they prefer.”
Fast Track is an FDA process designed to facilitate the development and expedite the review of potential therapies that seek to treat serious conditions and fill unmet medical needs. Programs with Fast Track designation may benefit from early and frequent communication with the FDA, eligibility for FDA accelerated approval, and priority review if relevant criteria are met, in addition to a rolling submission of the marketing application.
If you have a life-threatening food allergy, accurate food product labels are essential. With 32 million Americans at risk for anaphylaxis, with approximately six million of those being children, it can potentially be life-saving. Recently the Institute for the Advancement of Food and Nutrition Sciences (IAFNS) published a paper entitled “Trends in Food Allergy Research, Regulations and Patient Care”. This important paper provides " an overview of food allergies, their impact on affected individuals and caregivers, regulatory activities, and current research efforts to improve allergen management and patient care."
The Institute for the Advancement of Food and Nutrition Sciences (IAFNS) is a non-profit organization concerned with public health. Earlier this week, they published a paper entitled “Trends in Food Allergy Research, Regulations and Patient Care” that provides an overview of food allergies, their impact on affected individuals and caregivers, regulatory activities, and current research efforts to improve allergen management and patient care."
March Madness! This time of year, college basketball dominates the airwaves as well as so many discussions about which team is up, the biggest upset so far and how well your selection bracket is doing in the office pool. One of the all-time college basketball greats was Bill Walton. Walton also went on to earn several awards during his NBA career, despite having several injuries. A career that almost didn’t occur because of a near fatal bee sting in the Summer of 1973.
The first overall pick in the 1974 NBA Draft, Bill Walton had a star-crossed career because of injuries. But it nearly never happened at all.
by Phil Watson Originally published December 26, 2021
Article excerpt is reprinted with permission from author Phil Watson and posted on sportscasting.com
Bill Walton was one of the greatest college basketball players of all time. Despite a career as an NBA player marred by injuries, he won an NBA MVP, an NBA Finals MVP, and a pair of titles. But an incident between his junior and senior seasons at UCLA nearly ended his pro career before it started.
Walton, 69, remains one of the most colorful personalities in the game. He was the first player in NBA history to win MVP and Sixth Man of the Year honors. James Harden joined him in the exclusive club with his MVP win in 2017–18. Because of recurring foot and ankle problems, Walton’s career remains one of his era’s biggest “what-if” questions.
